THE ROLE OF IRON AND OTHER FACTORS IN PATIENTS UNRESPONSIVE TO ERYTHROPOIETIN THERAPY

[1] Association between recombi‐nant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis, Br Med J, 300, pp. 573-578, (1990)

[2] Kaupke CJ, Butler GC, Vaziri ND, Effect of recombinant human erythropoietin on platelet production in dialysis patients, J Am Soc Nephrol, 3, pp. 1672-1679, (1993)

[3] van Wyck DB, Iron management during recombinant human erythropoietin therapy, Am J Kidney Dis, 14, (1989)

[4] van Wyck DB, Iron deficiency in patients with dialysis‐associated anemia during ervthroooietin replacement therapy: Strategies for assessment ana management, Semin Nephrol, 9, 2 Sippl, (1989)

[5] Eschbach JW, Cook JD, Scribner BH, Finch CA, Iron balance in hemodialysis patients, Ann Intern Med, 87, pp. 710-713, (1977)

[6] van Wyck DB, Iron dextran in chronic renal failure, Semin Dialysis, 4, pp. 112-114, (1991)

[7] Macdougall IC, Allen D, Tucker B, Baker L, Raine A, Serum inter‐leukin‐6 levels are a useful indicator of marrow suppression in patients with resistance to erythropoietin due to inflammatory disease, (abstract), J Am Soc Nephrol, 4, (1993)

[8] Lee GR, The anemia of chronic disease, Semin Hematol, 20, pp. 61-80, (1983)

[9] Muirhead N, Hodsman AB, Occult infection and resistance of anaemia to rHuEPO therapy in renal failure, Nephrol Dial Transplant, 5, pp. 232-234, (1990)

[10] Adamson JW, Eschbach JW, Management of the anaemia of chronic renal failure with recombinant erythropoietin, Q J Med, 73, pp. 1093-1101, (1989)

[1] Association between recombi‐nant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis, Br Med J, 300, pp. 573-578, (1990)

[2] Kaupke CJ, Butler GC, Vaziri ND, Effect of recombinant human erythropoietin on platelet production in dialysis patients, J Am Soc Nephrol, 3, pp. 1672-1679, (1993)

[3] van Wyck DB, Iron management during recombinant human erythropoietin therapy, Am J Kidney Dis, 14, (1989)

[4] van Wyck DB, Iron deficiency in patients with dialysis‐associated anemia during ervthroooietin replacement therapy: Strategies for assessment ana management, Semin Nephrol, 9, 2 Sippl, (1989)

[5] Eschbach JW, Cook JD, Scribner BH, Finch CA, Iron balance in hemodialysis patients, Ann Intern Med, 87, pp. 710-713, (1977)

[6] van Wyck DB, Iron dextran in chronic renal failure, Semin Dialysis, 4, pp. 112-114, (1991)

[7] Macdougall IC, Allen D, Tucker B, Baker L, Raine A, Serum inter‐leukin‐6 levels are a useful indicator of marrow suppression in patients with resistance to erythropoietin due to inflammatory disease, (abstract), J Am Soc Nephrol, 4, (1993)

[8] Lee GR, The anemia of chronic disease, Semin Hematol, 20, pp. 61-80, (1983)

[9] Muirhead N, Hodsman AB, Occult infection and resistance of anaemia to rHuEPO therapy in renal failure, Nephrol Dial Transplant, 5, pp. 232-234, (1990)

[10] Adamson JW, Eschbach JW, Management of the anaemia of chronic renal failure with recombinant erythropoietin, Q J Med, 73, pp. 1093-1101, (1989)